dr. long on the rationale for the phase 3 combi-i trial in braf v600–mutant melanoma
Published 4 years ago • 170 plays • Length 1:17Download video MP4
Download video MP3
Similar videos
-
1:46
dr. long on the results of the pooled analysis of the combi-i trial in melanoma
-
1:52
dr. long on dabrafenib/trametinib in braf v600e-mutant melanoma
-
1:26
dr. nathan on long-term outcomes with dabrafenib/trametinib in braf v600-mutant melanoma
-
1:31
dr long on unmet needs in braf-mutant melanoma
-
1:42
dr. jason luke describes results from the phase iii combi-d trial
-
4:12
adjuvant therapy in melanoma: combi-ad trial
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
3:02
overall survival update from columbus trial in braf v600-mutant melanoma
-
4:45
combi-ad trial: adjuvant dabrafenib plus trametinib in patients with resected stage iii braf v60...
-
0:30
dr. postow on fda approval of adjuvant dabrafenib plus trametinib in braf-mutant melanoma
-
1:04
dr. wilson on long-term data with dabrafenib plus trametinib in melanoma
-
2:11
dr. keith t. flaherty on 3-year follow-up of combi-d in metastatic melanoma
-
1:11
dr. flaherty on resistance in braf-mutant melanoma
-
1:04
dr. schuchter on testing for a braf mutation in melanoma
-
7:02
triplet regimens in braf-mutant metastatic crc
-
6:12
braf as a driver in melanoma
-
27:28
advances in therapy for braf-mutant melanoma
-
6:33
treatment of braf-mutant metastatic melanoma
-
22:44
braf targeted therapy - melanoma education symposium, peter boasberg md